The prevalence of diabetes is still on the rise globally, becoming a chronic disease that poses a serious threat to human health. The data shows that the number of people with diabetes in China has exceeded 140 million, and it shows a trend of rejuvenation.
China has become truly the "world's largest diabetic power". However, the patient's blood sugar control situation is not optimistic, according to statistics, the blood glucose compliance rate of diabetic patients in China is only 15.8%.
Diabetes and its complications are placing a heavy burden on individuals, families and societies.
According to the Recent Global Diabetes Map (10th Edition) released by the International Diabetes Alliance, China's total expenditure on the treatment of diabetes and its complications will reach US$165.3 billion in 2021, ranking second in the world.
Cardiovascular diseases
Cause of death from type 2 diabetes mellitus
"As we all know, diabetes is not terrible, what is terrible is complications, including microvascular complications and macrovascular complications. Blood glucose control is not up to standard, and the management of cardiometabolic indicators such as blood pressure, blood lipids and body weight is poor, which has become the main reason for the high incidence of complications in Chinese diabetic patients. Professor Mu Yiming, director of the Department of Endocrinology of the First Medical Center of the PLA General Hospital, said in an interview with reporters.
Cardiovascular disease has become the main cause of death in patients with type 2 diabetes - the risk of cardio and cerebrovascular diseases in diabetic patients is 2 to 4 times that of non-diabetic people, and vascular complications shorten the life of patients by an average of 12 years.
It can be said that the damage of diabetes to the heart often occurs in silence. The data shows that 1 in every 3 type 2 diabetic patients in China has cardiovascular disease.
Previous clinical studies have shown that strict control of blood glucose can delay the progression of microvascular complications, but there is no significant reduction effect on large angiopathy.
Treating diabetes can not only focus on blood sugar,
It is necessary to improve the comprehensive compliance rate
The treatment of diabetes is not only a single control of blood glucose, it is necessary to take into account the "control of sugar" and "care of the heart", with the goal of improving cardiovascular and death outcomes, and comprehensive management of multiple cardiovascular metabolic risk factors, so as to delay the occurrence and development of complications, improve the long-term treatment outcomes of patients, and reduce the total treatment burden of diabetes.
From January 1, 2022, the new version of the national medical insurance drug list has been officially implemented. It is reported that the newly included drugs accurately complement the drug needs of tumors, chronic diseases, rare diseases, etc., involving a total of 21 clinical groups, and patients benefit from a wide range. The initial establishment of the dynamic adjustment mechanism of the national medical insurance directory has opened the door for innovative drugs to "run" into medical insurance.
In the field of diabetes treatment, the new hypoglycemic drug smegluotide injection is included in the reimbursement system of the national medical insurance directory. With the implementation of the new policy in various provinces and cities, it is accelerating the benefit of more type 2 diabetes patients in China.
In recent years, domestic and foreign guidelines have unanimously defined the important therapeutic status of GLP-1 receptor agonists (GLP-1 RA) for patients with type 2 diabetes mellitus with cardiovascular disease or cardiovascular risk.
Professor Mu Yiming said: "Diabetes treatment can not only focus on blood sugar, but also need to comprehensively consider metabolic abnormalities such as blood pressure, blood lipids and body weight, and improve the comprehensive compliance rate in order to maximize the benefits of patients." GLP-1 RA drugs provide a simple and effective treatment for the comprehensive management of diabetes. The inclusion in the medical insurance list is expected to help more patients with type 2 diabetes better carry out comprehensive disease management, effectively reduce or prevent related complications, improve the quality of life of patients, and achieve long-term benefits. ”
Improve adherence,
Optimize sugar control management
Diabetes is a chronic lifelong disease, "sugar friends" need long-term standardized treatment, adhere to a healthy lifestyle to improve the outcome of treatment, this long-term persistence is not easy.
In the daily treatment of diabetes, the choice of safe and effective drugs and the improvement of medication compliance are one of the elements of blood sugar control, and also an effective booster on the long journey.
"Compliance is a very important point in diabetes management, only by improving compliance can more patients be willing to use it, and the compliance rate can be higher in the future, which can really reduce the risk of cardiovascular disease, or improve the risk factors for cardiovascular disease." Professor Mu Yiming said.
Patient compliance is the basis for ensuring the effect of treatment, and improving compliance is the direction of drug research and development, and it is also an important reference factor for doctors' clinical drug selection.
Professor Mu Yiming said that in the current diabetes drugs, patients generally have the following characteristics:
Medication is simple. For example, if the drug is used once a week, the compliance is definitely better than the drug used three times a day, overcoming the complexity of most drug regimens and effectively improving the patient's treatment compliance.
The safety is high, and if there are serious side effects from the use of the drug, the patient is certainly reluctant to continue the drug.
Strong accessibility, medical insurance can be reimbursed.
The drug works well, and if the patient has been taking the drug for several months and finds that the effect is not achieved, he may give up.
Drugs that meet these standards must be good in compliance, and the higher the compliance of the drug, the easier it is for the patient to stick to it.
Professor Mu Yiming finally stressed that sugar control, in addition to blood glucose standards is the key, but also need to pay attention to cardiovascular complications, hoping that all sugar friends will win the "protracted war" of diabetes together. ▲
![With diabetes, these 6 things can not be forgotten, away from complications, and live as long as normal people![fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)